Free Trial
NASDAQ:COYA

Coya Therapeutics (COYA) Stock Price, News & Analysis

Coya Therapeutics logo
$6.12 +0.09 (+1.49%)
(As of 12:45 PM ET)

About Coya Therapeutics Stock (NASDAQ:COYA)

Key Stats

Today's Range
$6.05
$6.44
50-Day Range
$5.87
$10.19
52-Week Range
$4.75
$10.69
Volume
7,399 shs
Average Volume
71,353 shs
Market Capitalization
$102.27 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.67
Consensus Rating
Buy

Company Overview

Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic, which is in Phase 2 clinical trial for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. The company was incorporated in 2020 and is headquartered in Houston, Texas.

Coya Therapeutics Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
61st Percentile Overall Score

COYA MarketRank™: 

Coya Therapeutics scored higher than 61% of companies evaluated by MarketBeat, and ranked 527th out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Coya Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Coya Therapeutics has only been the subject of 2 research reports in the past 90 days.

  • Read more about Coya Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Coya Therapeutics are expected to decrease in the coming year, from ($1.15) to ($1.47) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Coya Therapeutics is -9.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Coya Therapeutics is -9.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Coya Therapeutics has a P/B Ratio of 3.14. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Coya Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    1.40% of the float of Coya Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Coya Therapeutics has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Coya Therapeutics has recently increased by 5.59%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Coya Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Coya Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.40% of the float of Coya Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Coya Therapeutics has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Coya Therapeutics has recently increased by 5.59%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Coya Therapeutics has a news sentiment score of 0.95. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 8 news articles for Coya Therapeutics this week, compared to 2 articles on an average week.
  • Search Interest

    7 people have searched for COYA on MarketBeat in the last 30 days. This is an increase of 250% compared to the previous 30 days.
  • MarketBeat Follows

    5 people have added Coya Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Coya Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $69,615.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    12.00% of the stock of Coya Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 39.75% of the stock of Coya Therapeutics is held by institutions.

  • Read more about Coya Therapeutics' insider trading history.
Receive COYA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Coya Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

COYA Stock News Headlines

Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners
Trump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code… And since then… "In the know" patriots have quietly used this same "Trump revenge loophole" to shield their life savings from Bidenomics…
Coya: COYA 301 – GLP-1 agonists combo synergistic in inflamation amelioration
Coya Therapeutics files to sell 1.38M shares of common stock for holders
What is HC Wainwright's Estimate for COYA FY2024 Earnings?
See More Headlines

COYA Stock Analysis - Frequently Asked Questions

Coya Therapeutics' stock was trading at $7.41 on January 1st, 2024. Since then, COYA shares have decreased by 18.6% and is now trading at $6.03.
View the best growth stocks for 2024 here
.

Coya Therapeutics, Inc. (NASDAQ:COYA) announced its quarterly earnings data on Wednesday, November, 6th. The company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($0.41) by $0.15.

Coya Therapeutics (COYA) raised $15 million in an initial public offering (IPO) on Thursday, December 29th 2022. The company issued 3,050,000 shares at a price of $5.00 per share.

Top institutional investors of Coya Therapeutics include Geode Capital Management LLC (0.85%) and GHP Investment Advisors Inc. (0.18%). Insiders that own company stock include David S Snyder, Arun Swaminathan and Fred Grossman.
View institutional ownership trends
.

Shares of COYA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Coya Therapeutics investors own include Broadcom (AVGO), NVIDIA (NVDA), Arista Networks (ANET), Disc Medicine (IRON), Jabil (JBL), Adobe (ADBE) and e.l.f. Beauty (ELF).

Company Calendar

Last Earnings
11/06/2024
Today
11/21/2024
Fiscal Year End
12/31/2024
Next Earnings (Estimated)
3/18/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:COYA
Fax
N/A
Employees
6
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$16.67
High Stock Price Target
$18.00
Low Stock Price Target
$14.00
Potential Upside/Downside
+176.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-7,990,000.00
Pretax Margin
-104.42%

Debt

Sales & Book Value

Annual Sales
$6 million
Book Value
$1.92 per share

Miscellaneous

Free Float
14,702,000
Market Cap
$100.76 million
Optionable
Not Optionable
Beta
0.46
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.

Get This Free Report

This page (NASDAQ:COYA) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners